Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Expands Mavacamten Indication to Pediatric Obstructive HCM Patients

1 October 2026 · By · Wire by Fusion42

Published

1 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tctmd.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

The FDA has expanded the approved use of mavacamten to include pediatric patients with obstructive hypertrophic cardiomyopathy (HCM), potentially broadening treatment options for younger patients with this condition.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 30 Sep 2026 and 2 Oct 2026.

◆ ◆ The Wire takeaway

You can now explore pediatric markets for mavacamten in obstructive HCM, opening new clinical and commercial opportunities. Paediatric cardiology startups should accelerate trials or partnerships to capture this newly validated segment.

◆ Coverage

3 sources · first reported 30 Sep 2026 · latest 2 Oct 2026

◆ Related on Wire

◆ Topics

BiotechFDAmavacamtenpediatric-HCMdrug-approvalregulatory-expansion